This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Janssen Korea.
Reference
Lee H-Y, et al. Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. ClinicoEconomics and Outcomes Research : 3 Jul 2013. Available from: URL: http://dx.doi.org/10.2147/CEOR.S42170
Rights and permissions
About this article
Cite this article
Liposomal doxorubicin/carboplatin preferred in ovarian cancer. PharmacoEcon Outcomes News 683, 5 (2013). https://doi.org/10.1007/s40274-013-0568-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0568-2